Alluvi tirzepatide 40mg is supplied strictly for research and development purposes only and is not intended for human or veterinary use
Clinical trials demonstrated infrequent hypoglycemia with tirzepatide alone, but risk increases substantially when combined with insulin or sulfonylureas
You understand and accept the regulatory and quality considerations involved
Most people start with 0.25 mg to 1 mg each week
Oral formulations have a shorter half-life.[ref] In clinical trials, GLP-1 RAs improved lipid profiles, increased satiety, slowed gastric emptying, reduced inflammation, and had neuroprotective effects.[ref] The slowing of gastric emptying and reducing inflammation may play a role in weight loss, along with the decrease in appetite and eating less
This leads to reduced hunger, lower caloric consumption, and, consequently, weight loss